[HTML][HTML] The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era

Z Lwin, JW Riess, D Gandara - Journal of thoracic disease, 2013 - ncbi.nlm.nih.gov
There have been remarkable advances in the targeted treatment of advanced non-small cell
lung cancer (NSCLC) over the past several years. Survival outcomes are steadily improving …

Advances in chemotherapy in advanced non-small-cell lung cancer

P Maione, A Rossi, PC Sacco… - Expert opinion on …, 2010 - Taylor & Francis
Importance of the field: Lung cancer is the most common cancer in the world today, in terms
of both incidence and mortality. Non-small-cell lung cancer (NSCLC) accounts for about …

[HTML][HTML] Review of the current targeted therapies for non-small-cell lung cancer

KSH Nguyen, JW Neal, H Wakelee - World journal of clinical …, 2014 - ncbi.nlm.nih.gov
The last decade has witnessed the development of oncogene-directed targeted therapies
that have significantly changed the treatment of non-small-cell lung cancer (NSCLC). In this …

Targeted therapies for advanced non-small-cell lung cancer: current status and future implications

A Custodio, M Méndez, M Provencio - Cancer treatment reviews, 2012 - Elsevier
Lung cancer remains the leading cause of malignancy-related mortality worldwide, with over
one million cases diagnosed yearly. Non-small-cell lung cancer (NSCLC) accounts for> …

Advances in the treatment of non-small cell lung cancer

L Horn - Journal of the National Comprehensive Cancer …, 2014 - jnccn.org
Clinical trial data continue to emerge on treatments in advanced non-small cell lung cancer
(NSCLC), supporting the strategy that histology and molecular driver mutations should guide …

[HTML][HTML] The emerging treatment landscape of advanced non-small cell lung cancer

P Economopoulou, G Mountzios - Annals of Translational Medicine, 2018 - ncbi.nlm.nih.gov
Lung cancer remains the leading cause of cancer related death worldwide. Despite broad
advances in diagnostics and therapy, the five-year overall survival for patients with …

Treatment paradigms in advanced non-small-cell lung cancer.

CE McCoach, K Kelly - Clinical Advances in Hematology and …, 2013 - escholarship.org
Lung cancer is the most common cause of cancer-related death worldwide, owing to its
metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care …

Targeted therapies for non-small cell lung cancer

GS Papaetis, C Roussos… - Current pharmaceutical …, 2007 - ingentaconnect.com
Conventional therapy for non-small cell lung cancer (NSCLC) has reached a plateau in
increasing patient survival and overall prognosis still remains dismal. Advances in the …

Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development

D Mahalingam, A Mita, MM Mita, ST Nawrocki… - Current problems in …, 2009 - Elsevier
N on-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide,
although evidence now suggests that novel biological agents could improve survival of …

Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.

J Auberger, J Loeffler-Ragg, W Wurzer… - Current cancer drug …, 2006 - ingentaconnect.com
Targeted therapies focus on signaling pathways in cancer cells and other molecular
processes involved in oncogenesis. Recent approaches affect the following major groups …